Carbapenem-Based Antibiotics Market Size | Report 2021, 2028

Carbapenem-Based Antibiotics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Meropenem, Doripenem, Imipenem, Tebipenem, and Others), Indication (Bacterial Meningitis, Acute Pelvic Infections, Respiratory Tract Infections, Intra-Abdominal Infections, Urinary Tract Infections, and Others), and Distribution Channel (Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies)

  • Report Code : TIPRE00027228
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 180
Buy Now

The carbapenem-based antibiotics market size is expected to grow from US$ 3,964.57 million in 2021 to US$ 5,346.62 million by 2028; it is estimated to grow at a CAGR of 4.4% during 2021-2028.

Carbapenems are type of atypical β-lactam antibiotics that have wider antibacterial activity. Carbapenem-based antibiotics can cover many gram-positive, gram-negative aerobic, and anaerobic bacteria. Additionally, carbapenem-based antibiotics are stable to most β-lactamases. Hence, they are indicated as empiric monotherapy for various serious conditions, such as neutropenic infections and intra-abdominal infections.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Carbapenem-Based Antibiotics Market: Strategic Insights

carbapenem-based-antibiotics-market
Market Size Value inUS$ 3,964.57 Million in 2021
Market Size Value byUS$ 5,346.62 Million by 2028
Growth rateCAGR of 4.4% from 2021 to 2028
Forecast Period2021-2028
Base Year2021
Analyst Image

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst


The rising prevalence of gram-negative bacterial infections and the increasing production of generic drugs fuel the growth of the carbapenem-based antibiotics market. However, tedious and expensive process of antibiotic development restrains the market growth.

Global Carbapenem-Based Antibiotics Market

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Market Insights
Rising Prevalence of Gram-Negative Bacterial Infections

Gram-negative bacterial infections, such as urinary tract infection (UTI), pneumonia, bloodstream infections, wound or surgical site infections, and meningitis, are commonly acquired by patients during their hospital stays. These infections are generally known as hospital-acquired infections (HAI). Infections such as UTI and pneumonia are common in patients admitted to intensive care units. According to the US National Healthcare Safety Network, 30% of HAIs are caused by gram-negative bacteria, ~45% are due to UTI, and ~47% are by ventilator-associated pneumonia (VAP). The prevalence of infectious diseases caused by gram-negative bacteria is rapidly increasing.

In addition, gram-negative bacterial infections are resistant to multiple drugs and have developed better resistance to available antibiotics. Antimicrobial resistance (AMR) has become a global threat to modern medicine. Therefore, constant monitoring of emerging trends is required for the clinical isolates. A group of researchers in Latvia, Europe, has studied the progression of AMR for different gram-negative bacteria. As per the research article published by them in the MDPI journal in June 2021, carbapenem-based antibiotics such as Meropenem and Ertapenem were the most effective against gram-negative bacteria, showing 3% and 5.4% resistance rates, respectively. These antibiotics are globally accepted as a treatment for gram-negative bacteria. Therefore, it is estimated that the high demand for carbapenem-based antibiotics is likely to continue in the coming years.

According to the Centers for Disease Control and Prevention (CDC), the COVID-19 pandemic led to the rise in HAI cases in 2020. Hospital admissions have grown globally, which has increased the risk of VAP as a secondary infection for COVID-19 patients. This has resulted in fueled demand for carbapenem-based antibiotics, which is aiding the market significantly.

Type-Based Insights

The carbapenem-based antibiotics market, by type, is segmented into meropenem, doripenem, imipenem, tebipenem, and others. The others segment held the largest share of the carbapenem-based antibiotics market in 2021, and it is anticipated to register the highest CAGR in the market during the forecast period. The growing developments for carbapenem-based antibiotics are likely to drive the market growth in the future.

Carbapenem-Based Antibiotics Market Share, by Type – 2021 and 2028

pharmaceuticals
Carbapenem-Based Antibiotics Market Share, by Type – 2021 and 2028
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Indication-Based Insights

By indication, the carbapenem-based antibiotics market is segmented into bacterial meningitis, acute pelvic infections, respiratory tract infections, intra-abdominal infections, urinary tract infections, and others. The others segment held the largest share of the carbapenem-based antibiotics market in 2021, and it is estimated to register the highest CAGR in the market during the forecast period. The uncertainty of bacterial infections propels the demand for carbapenem-based antibiotics, which is expected to drive the growth of market in the coming years.

Distribution Channel-Based Insights

By distribution channel, the carbapenem-based antibiotics market is segmented into retail pharmacies, online pharmacies, and hospital pharmacies. The hospital pharmacies segment held the largest share of the carbapenem-based antibiotics market in 2021, and it is estimated to register the highest CAGR in the market during the forecast period.

 

Organic strategies, such as new product launch, is commonly adopted by companies to expand their product portfolios in the market. Moreover, the companies have implemented various inorganic strategies, such as mergers and acquisitions and partnerships. For instance, in May 2021, Gland Pharma Limited in association with Dr Reddy's Laboratories Ltd launched Ertapenem for Injection, 1 g/vial, a therapeutic equivalent to generic version of INVANZ (ertapenem for injection) for injection) 1 g/vial, which is approved by the US Food and Drug Administration (USFDA).

Company Profiles

  • Pfizer Inc.
  • Savior Lifetec
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Merck & Co., Inc.
  • Gland Pharma Limited
  • Aurobindo Pharma Ltd
  • DAEWOONG PHARMACEUTICAL CO.,LTD
  • Iterum Therapeutics plc
  • ACS Dobfar S.p.A
  • Spero Therapeutics
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Type, Indication, and Distribution Channel

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States

Frequently Asked Questions


What are the carbapenem-based antibiotics?

Carbapenems are type of atypical β-lactam antibiotics that have wider antibacterial activity. Carbapenem-based antibiotics can cover many gram-positive, gram-negative aerobic, anaerobic bacteria. Additionally, carbapenem-based antibiotics are stable to most β-lactamases and hence, are indicated as empiric monotherapy for various serious conditions such as neutropenic infections and intra-abdominal infections.

What are the driving factors for the global carbapenem-based antibiotics market across the world?

The factors that are driving the growth of market are growing rising prevalence of gram-negative bacterial infections and increasing production of generic drugs fuel the growth of the market. However, the tedious and expensive process of antibiotic development, as well as approval, is the major factor hindering the market growth.

Who are the major players in market the carbapenem-based antibiotics market?

The carbapenem-based antibiotics market majorly consists of the players such as Pfizer Inc.; Savior Lifetec; Sumitomo Dainippon Pharma Co., Ltd.; Merck & Co., Inc.; Gland Pharma Limited; Aurobindo Pharma Ltd; Daewoong Pharmaceutical Co.,Ltd; Iterum Therapeutics plc; ACS Dobfar S.p.A, and Spero Therapeutics among others.

Which segment is dominating the carbapenem-based antibiotics market?

The carbapenem-based antibiotics market is analyzed in the basis of type, indication, and distribution channel. Based on type, is segmented into meropenem, doripenem, imipenem, tebipenem, and others. The others segment held the largest share of the market, and it is anticipated to register the highest CAGR. Based indication, the market is segmented as bacterial meningitis, acute pelvic infections, respiratory tract infections, intra-abdominal infections, urinary tract infections, and others. The others segment held the largest share of the market, and it is estimated to register the highest CAGR. And based on distribution channel, the market is divided into retail pharmacies, online pharmacies, and hospital pharmacies. The hospital pharmacies segment held the largest share of the market, and it is estimated to register the highest CAGR.

The List of Companies - Carbapenem Based Antibiotics Market

  1. Pfizer Inc.
  2. Savior Lifetec
  3. Sumitomo Dainippon Pharma Co., Ltd.
  4. Merck & Co., Inc.
  5. Gland Pharma Limited
  6. Aurobindo Pharma Ltd
  7. Daewoong Pharmaceutical Co.,Ltd,
  8. Iterum Therapeutics plc
  9. ACS Dobfar S.p.A
  10. Spero Therapeutics

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Carbapenem-Based Antibiotics Market